NCT07429227Recruiting
Evaluation Through Innovative Examinations of Intestinal Dysbiosis Status in Patients Diagnosed With Cardiovascular Diseases and Evaluation of the Efficacy of Natural and Probiotic Extracts in the Non-pharmacological Approach to Improving Intestinal Dysbiosis Status.
Metabolomic and Cellular Inflammaging Investigation Study of Patients With Acute Coronary Syndrome (ACS)
Source: ClinicalTrials.gov · Last updated 24 Feb 2026
Brief summary (registry, in English)
The prospective experimental study aims to take an instantaneous photograph of the subject at time T0 and after 24 hours of intestinal permeability and dysbiosis indices in patients with acute coronary syndromes (ACS) which include unstable coronary artery disease (unstable angina) and acute myocardial infarction (AMI). The aim is to verify whether essential oils in particular formulations with high bioavailability are able to re-establish intestinal eubiosis after 2 months, confirmed by tests laboratory specifics such as metabolomics.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 15 (estimated)
- First submitted
- 10 Feb 2026
- Start date
- 1 Mar 2026
- Primary completion date
- 31 Mar 2027
- Lead sponsor
- Casa di Cura Dott. Pederzoli
- Diseases
- Coronary artery disease
- NCT number
- NCT07429227
What you commit to
- Study type: Interventional
- Planned participants: 15
- From 1 Mar 2026 to the primary completion date, 31 Mar 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Use in the three months preceding the signing of the informed consent of:
- Lipid-lowering drugs containing statins, ezetimibe, fibrates ii) Lipid-lowering nutraceuticals containing monacolin K iii) Monoclonal antibodies that inhibit PCSK9 (proprotein convertase subtilisin/kexin type 9) such as Evolocumab and Alirocumab
Other illness
- Diagnosis of conditions such as HIV, cancer and diabetes I and II Furthermore, if a female patient becomes pregnant during the trial, this will be one of the reasons for early exit from the study.
Who the study is looking for
- 1\. Signing of informed consent
- 2\. Diagnosis of Acute Coronary Syndrome (ACS)
- 3\. Age 30-70
Age in the registry: 30 years to 70 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Ospedale P. Pederzoli Casa di Cura Privata S.p.A. Coordinator of this site? Confirm its status | Peschiera del Garda | Italy | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.